Any feedback?
Literature summary for 3.4.14.5 extracted from
- Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes (2006), J. Am. Board. Fam. Med., 19, 612-620.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | DPP-IV inhibitors in treatment of type 2 diabetes | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| additional information | DPP-IV inhibitors suppress the degradation of a variety of bioactive peptides, including GLP-1 | Homo sapiens | |
| saxagliptin | - |
Homo sapiens |  |
| sitagliptin | - |
Homo sapiens | |
| vildagliptin | - |
Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
